Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07175441 · ClinicalTrials.gov registry record · Phase 2
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
A Phase 2 study of Advanced Unresectable Hepatocellular Carcinoma, sponsored by Riboscience.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
- 3
- Study locations
NCT07175441 is a Phase 2 study of Advanced Unresectable Hepatocellular Carcinoma that is actively recruiting participants, run by Riboscience. The registered enrollment target is 220 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT07175441, a Phase 2 study of Advanced Unresectable Hepatocellular Carcinoma, is actively recruiting participants, sponsored by Riboscience.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
- 3
- Study locations
Study Summary
RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis, thereby activating antigen-presenting cells and promoting robust T cell activation. Ideally, RBS2418 acts synergistically with CTLA-4 inhibitors, such as those in the STRIDE regimen (Tremelimumab plus Durvalumab). The hypothesis is that RBS2418 combined with STRIDE will be safe, well-tolerated, highly immunogenic, and enhance anti-tumor responses in adult participants with advanced, unresectable hepatocellular carcinoma (HCC) compared to STRIDE alone.
Conditions Studied
Interventions
- DRUG RBS2418
- DRUG STRIDE (durvalumab + tremelimumab)
Study Locations (3)
Maryland
- Johns Hopkins - Baltimore
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Texas
- START Dallas Fort Worth - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2026-04 |
| Est. Completion | 2027-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07175441
The ClinicalTrials.gov registry entry for NCT07175441 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Riboscience, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Unresectable Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which RBS2418 is the first listed.
NCT07175441 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Maryland, Tennessee, Texas.
Frequently Asked Questions
What is clinical trial NCT07175441 about?
NCT07175441 is a clinical study titled "Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma". RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis, thereby activating antigen-pre...
What is the current status of trial NCT07175441?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2026-04. Estimated completion is 2027-08.
What conditions does trial NCT07175441 study?
This clinical trial studies the following conditions: Advanced Unresectable Hepatocellular Carcinoma.
What interventions are being tested in trial NCT07175441?
The interventions under investigation include: RBS2418 (DRUG), STRIDE (durvalumab + tremelimumab) (DRUG).
Who is sponsoring clinical trial NCT07175441?
This trial is sponsored by Riboscience, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07175441 being conducted?
This trial has 3 study locations across Maryland, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.